New vaccine aims to shield against multiple sarbecoviruses
NCT ID NCT07280858
First seen Jan 05, 2026 · Last updated Jun 14, 2026 · Updated 18 times
Summary
This study tests a new vaccine called GBP511, designed to protect against a family of viruses called sarbecoviruses (which includes SARS-CoV-2). The trial involves about 368 healthy adults aged 18 and older. Researchers will check the vaccine's safety and how well it triggers the body's immune defenses, with some doses including an extra ingredient (adjuvant) to boost the response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Linear
RECRUITINGNedlands, Western Australia, 6009, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Momentum Clinical Research Darlinghurst
NOT_YET_RECRUITINGSydney, Kent Street, 309, Level 9, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.